Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aardvark Therapeutics, Inc.AARD · Entity 6598 | Director | August 14, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aardvark Therapeutics, Inc.
Report date August 14, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.54 · Expires 2036-08-14 | Direct | 44,964 |
Reported balance
After 2026-08-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 44,964 · Balance 44,964 F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Scilex Holding Co
Report date November 10, 2022 · Filed November 16, 2022
Jointly reported with Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Ho Chris
Section 16 reporting ended · disclosed 2022-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2027-11-10 | IndirectBy Vickers Venture Fund VI Pte Ltd | 901,000 |
Reported balance
After 2022-11-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-10 · Other · Disposed 5,261,840 · Balance 901,000 F1: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I F2: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2027-11-10 | IndirectBy Vickeres Venture Fund VI (Plan) Pte Ltd | 99,000 |
Reported balance
After 2022-11-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-10 · Other · Disposed 578,160 · Balance 99,000 F1: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I F2: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I
F2: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 21, 2026 23:48 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 44,964 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001193125-26-361489 · ownership.xml · derivative · entry 1 Chi Jeffrey · CIK 0001839163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,964 Underlying: Common Stock · 44,964 shares Expires 2036-08-14 F1 · derivative.exercise_date: The option shall vest in full on the earlier of (i) August 14, 2027, and (ii) immediately prior to the Registrant's next Annual Meeting of Stockholders following the date of grant, subject to the Reporting Person's continuous service through the applicable vesting date, inclusive. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:05 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | GrantStock Option (right to buy) · Derivative | 61,017 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086146 · ownership.xml · derivative · entry 1 Chi Jeffrey · CIK 0001839163 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,017 Underlying: Common Stock · 61,017 shares Expires 2035-06-11 F1 · derivative.exercise_date: 1/3rd of the shares subject to the option will vest on June 11, 2026, and 1/36th of the shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:57 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,130,135 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023311 · ownership.xml · derivative · entry 2 Chi Jeffrey · CIK 0001839163 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vickers Venture Co-investment LLC Disclosed balance after: 0 Underlying: Common Stock · 133,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Vickers Venture Co-investment LLC ("Vickers Co-investment") is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Each of Vickers Venture Partners (S) Pte. Ltd., Dr. Jeffrey Chi and Dr. Finian Tan disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:57 UTC | Aardvark Therapeutics, Inc. AARD · Entity 6598 | ConversionCommon Stock | 133,364 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023311 · ownership.xml · nonDerivative · entry 1 Chi Jeffrey · CIK 0001839163 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Vickers Venture Co-investment LLC Disclosed balance after: 133,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Vickers Venture Co-investment LLC ("Vickers Co-investment") is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its directors, being Dr. Jeffrey Chi and Dr. Finian Tan, who collectively exercise sole voting and dispositive power over the securities held by Vickers Co-investment. Each of Vickers Venture Partners (S) Pte. Ltd., Dr. Jeffrey Chi and Dr. Finian Tan disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| November 10, 2022 Filed Nov 16, 2022 02:47 UTC | Scilex Holding Co VCKAU · Entity 7345 | OtherWarrants · Derivative | 578,160 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001104659-22-119278 · tm2229408-1_4seq1.xml · derivative · entry 2 Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner · See footnote (1) Vickers Venture Fund VI (Plan) Pte Ltd · CIK 0001839160 · See footnote (1) Chi Jeffrey · CIK 0001839163 · See footnote (1) Ho Chris · CIK 0001838628 · See footnote (1) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vickeres Venture Fund VI (Plan) Pte Ltd Disclosed balance after: 99,000 Underlying: Common Stock · 578,160 shares Expires 2027-11-10 F1 · kind: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I F2 · kind: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. F2 · price: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. Read SEC document |
| November 10, 2022 Filed Nov 16, 2022 02:47 UTC | Scilex Holding Co VCKAU · Entity 7345 | OtherWarrants · Derivative | 5,261,840 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001104659-22-119278 · tm2229408-1_4seq1.xml · derivative · entry 1 Vickers Venture Fund VI Pte Ltd · CIK 0001839162 · 10% owner · See footnote (1) Vickers Venture Fund VI (Plan) Pte Ltd · CIK 0001839160 · See footnote (1) Chi Jeffrey · CIK 0001839163 · See footnote (1) Ho Chris · CIK 0001838628 · See footnote (1) Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vickers Venture Fund VI Pte Ltd Disclosed balance after: 901,000 Underlying: Common Stock · 5,261,840 shares Expires 2027-11-10 F1 · kind: Effective November 10, 2022, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (and indirectly by its managing members, Jeffrey Chi, the Issuer's Chief Executive Officer, and Christopher Ho, the Issuer's Chief Financial Officer) are no longer 10% Holders of Vickers Vantage Corp. I F2 · kind: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. F2 · price: In connection with the business combination between Scilex Holding Company (f/k/a Vickers Vantage Corp. I) with Scilex, Inc. (f/k/a Scilex Holding Company, (i) Vickers Venture Fund VI Pte Ltd forfeited 2,465,136 warrants to purchase common shares of Scilex Holding Company ("New Scilex Warrants") and transferred 2,796,704 New Scilex Warrants to to Sorrento Therapeutics, Inc. ("Sorrento") and (ii) Vickers Venture Fund VI (Plan) Pte Ltd forfeited 270,864 New Scilex Warrants and transferred 307,296 to Sorrento. Following such transfers and the forfeitures (i) Vickers Venture Fund VI Pte Ltd holds 901,000 New Scilex Warrants and (ii) Vickers Venture Fund VI (Plan) Pte Ltd holds 99,000 New Scilex Warrants. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.